ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI posted its earnings results on Tuesday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05, Zacks reports.
ESSA Pharma Price Performance
NASDAQ:EPIX traded up $0.01 on Tuesday, hitting $1.64. 296,440 shares of the company's stock were exchanged, compared to its average volume of 297,375. The firm has a 50-day moving average price of $3.18 and a 200-day moving average price of $4.67. The company has a market cap of $72.77 million, a P/E ratio of -2.63 and a beta of 1.62. ESSA Pharma has a 52 week low of $1.40 and a 52 week high of $11.67.
Insider Activity
In other ESSA Pharma news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $1.53, for a total transaction of $12,055,761.99. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 14.70% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on EPIX. Jefferies Financial Group downgraded ESSA Pharma from a "buy" rating to a "hold" rating in a research report on Monday, November 4th. Oppenheimer cut shares of ESSA Pharma from an "outperform" rating to a "market perform" rating in a research report on Monday, November 4th. Finally, Piper Sandler lowered shares of ESSA Pharma from an "overweight" rating to a "neutral" rating and lowered their target price for the stock from $15.00 to $2.00 in a report on Monday, November 4th.
View Our Latest Report on ESSA Pharma
ESSA Pharma Company Profile
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Recommended Stories
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
